Cargando…
Veterinary vaccine development from an industrial perspective
Veterinary vaccines currently available in Europe and in other parts of the world are developed by the veterinary pharmaceutical industry. The development of a vaccine for veterinary use is an economic endeavour that takes many years. There are many obstacles along the path to the successful develop...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110856/ https://www.ncbi.nlm.nih.gov/pubmed/18313956 http://dx.doi.org/10.1016/j.tvjl.2007.11.009 |
_version_ | 1783513153445822464 |
---|---|
author | Heldens, J.G.M. Patel, J.R. Chanter, N. ten Thij, G.J. Gravendijck, M. Schijns, V.E.J.C. Langen, A. Schetters, Th.P.M. |
author_facet | Heldens, J.G.M. Patel, J.R. Chanter, N. ten Thij, G.J. Gravendijck, M. Schijns, V.E.J.C. Langen, A. Schetters, Th.P.M. |
author_sort | Heldens, J.G.M. |
collection | PubMed |
description | Veterinary vaccines currently available in Europe and in other parts of the world are developed by the veterinary pharmaceutical industry. The development of a vaccine for veterinary use is an economic endeavour that takes many years. There are many obstacles along the path to the successful development and launch of a vaccine. The industrial development of a vaccine for veterinary use usually starts after the proof of concept that is based on robust academic research. A vaccine can only be made available to the veterinary community once marketing authorisation has been granted by the veterinary authorities. This review gives a brief description of the regulatory requirements which have to be fulfilled before a vaccine can be admitted to the market. Vaccines have to be produced in a quality controlled environment to guarantee delivery of a product of consistent quality with well defined animal and consumer safety and efficacy characteristics. The regulatory and manufacturing legislative framework in which the development takes place is described, as well as the trend in developments in production systems. Recent developments in bacterial, viral and parasite vaccine research and development are also addressed and the development of novel adjuvants that use the expanding knowledge of immunology and disease pathology are described. |
format | Online Article Text |
id | pubmed-7110856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71108562020-04-02 Veterinary vaccine development from an industrial perspective Heldens, J.G.M. Patel, J.R. Chanter, N. ten Thij, G.J. Gravendijck, M. Schijns, V.E.J.C. Langen, A. Schetters, Th.P.M. Vet J Article Veterinary vaccines currently available in Europe and in other parts of the world are developed by the veterinary pharmaceutical industry. The development of a vaccine for veterinary use is an economic endeavour that takes many years. There are many obstacles along the path to the successful development and launch of a vaccine. The industrial development of a vaccine for veterinary use usually starts after the proof of concept that is based on robust academic research. A vaccine can only be made available to the veterinary community once marketing authorisation has been granted by the veterinary authorities. This review gives a brief description of the regulatory requirements which have to be fulfilled before a vaccine can be admitted to the market. Vaccines have to be produced in a quality controlled environment to guarantee delivery of a product of consistent quality with well defined animal and consumer safety and efficacy characteristics. The regulatory and manufacturing legislative framework in which the development takes place is described, as well as the trend in developments in production systems. Recent developments in bacterial, viral and parasite vaccine research and development are also addressed and the development of novel adjuvants that use the expanding knowledge of immunology and disease pathology are described. Elsevier Ltd. 2008-10 2008-03-03 /pmc/articles/PMC7110856/ /pubmed/18313956 http://dx.doi.org/10.1016/j.tvjl.2007.11.009 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Heldens, J.G.M. Patel, J.R. Chanter, N. ten Thij, G.J. Gravendijck, M. Schijns, V.E.J.C. Langen, A. Schetters, Th.P.M. Veterinary vaccine development from an industrial perspective |
title | Veterinary vaccine development from an industrial perspective |
title_full | Veterinary vaccine development from an industrial perspective |
title_fullStr | Veterinary vaccine development from an industrial perspective |
title_full_unstemmed | Veterinary vaccine development from an industrial perspective |
title_short | Veterinary vaccine development from an industrial perspective |
title_sort | veterinary vaccine development from an industrial perspective |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110856/ https://www.ncbi.nlm.nih.gov/pubmed/18313956 http://dx.doi.org/10.1016/j.tvjl.2007.11.009 |
work_keys_str_mv | AT heldensjgm veterinaryvaccinedevelopmentfromanindustrialperspective AT pateljr veterinaryvaccinedevelopmentfromanindustrialperspective AT chantern veterinaryvaccinedevelopmentfromanindustrialperspective AT tenthijgj veterinaryvaccinedevelopmentfromanindustrialperspective AT gravendijckm veterinaryvaccinedevelopmentfromanindustrialperspective AT schijnsvejc veterinaryvaccinedevelopmentfromanindustrialperspective AT langena veterinaryvaccinedevelopmentfromanindustrialperspective AT schettersthpm veterinaryvaccinedevelopmentfromanindustrialperspective |